Evaluation of the morphological features and unfavorable prognostic impact of dirty necrosis in renal cell carcinoma.


Journal

Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 14 10 2020
accepted: 12 12 2020
pubmed: 22 1 2021
medline: 26 3 2021
entrez: 21 1 2021
Statut: ppublish

Résumé

Tumor necrosis (TN) is one of the unfavorable prognostic factors in renal cell carcinoma (RCC). We identified two patterns of TN according to their morphology: dirty necrosis and ghost necrosis. We aimed to elucidate the morphological features and unfavorable prognostic impact of dirty necrosis in RCC. A total of 261 tumors collected after nephrectomy, which were pathologically identified as RCC, were analyzed in this study. We classified TN as dirty necrosis or ghost necrosis and compared their clinicopathological features. We also assessed their morphological features using digitally analyzed slides. The correlation between tumor size and necrosis area or the number of necrotic foci was calculated. There were 77 tumors (30%) with TN, and the presence of TN was significantly associated with unfavorable clinicopathological factors. Thirty tumors (39%) had dirty necrosis, and 47 tumors (61%) had ghost necrosis. There were significantly higher numbers of unfavorable factors associated with dirty necrosis than with ghost necrosis. In dirty necrosis, both the TN area and the number of necrotic foci were correlated with tumor size (p < 0.001 and p = 0.003, respectively). However, in ghost necrosis, no correlation was found between tumor size and the number of necrotic foci (p = 0.58). Tumors (without stage IV) with dirty necrosis had a significantly shorter disease-free survival time than those with ghost necrosis and those without TN (p = 0.024 and p < 0.001, respectively). Dirty necrosis has potential as an unfavorable prognostic indicator of surgically resected RCC.

Identifiants

pubmed: 33475860
doi: 10.1007/s00432-020-03505-2
pii: 10.1007/s00432-020-03505-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1089-1100

Subventions

Organisme : National Cancer Research Fund
ID : 31-A-6

Références

Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16:431–446. https://doi.org/10.1038/nrc.2016.52
doi: 10.1038/nrc.2016.52 pubmed: 27282249
Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Coughlin G, Dunglison N et al (2019) Assessment of tumour-associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma. Histopathology 74:284–290. https://doi.org/10.1111/his.13737
doi: 10.1111/his.13737 pubmed: 30129659
Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J et al (2013) The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 37:1490–1504. https://doi.org/10.1097/PAS.0b013e318299f0fb
doi: 10.1097/PAS.0b013e318299f0fb pubmed: 24025520
Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–1659. https://doi.org/10.1056/NEJM198612253152606
doi: 10.1056/NEJM198612253152606 pubmed: 3537791
Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663. https://doi.org/10.1097/00000478-198210000-00007
doi: 10.1097/00000478-198210000-00007 pubmed: 7180965
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P et al (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25:486–541. https://doi.org/10.1038/s41418-017-0012-4
doi: 10.1038/s41418-017-0012-4 pubmed: 29362479 pmcid: 5864239
Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D et al (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21:938–945. https://doi.org/10.1038/nm.3909
doi: 10.1038/nm.3909 pubmed: 26193342 pmcid: 4852857
Giordano TJ, Chrousou GP, de Krijger RR, Gill A, Kawashima A, Koch CA et al (2017) Tumours of the adrenal cortex. In: Lloyd RV, Osamura RY, Klőppel G, Rosai J (eds) WHO classification of tumours of the endocrine organs, 4th edn. IARC, Lyon, pp 163–168
Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H (2009) Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 27:4709–4717. https://doi.org/10.1200/JCO.2008.18.9498
doi: 10.1200/JCO.2008.18.9498 pubmed: 19720929
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/bmt.2012.244
doi: 10.1038/bmt.2012.244 pubmed: 23208313
Khor LY, Dhakal HP, Jia X, Reynolds JP, McKenney JK, Rini BI et al (2016) Tumor necrosis adds prognostically significant information to grade in clear cell renal cell carcinoma: a study of 842 consecutive cases from a single institution. Am J Surg Pathol 40:1224–1231. https://doi.org/10.1097/PAS.0000000000000690
doi: 10.1097/PAS.0000000000000690 pubmed: 27428737
Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B et al (1997) The Heidelberg classification of renal cell tumours. J Pathol 183:131–133. https://doi.org/10.1002/(SICI)1096-9896(199710)183:2%3C131::AID-PATH931%3E3.0.CO;2-G
doi: 10.1002/(SICI)1096-9896(199710)183:2%3C131::AID-PATH931%3E3.0.CO;2-G pubmed: 9390023
Li L, Jiang W, Yang Y, Chen Z, Feng C, Li H et al (2014) Identification of dirty necrosis in colorectal carcinoma based on multiphoton microscopy. J Biomed Opt 19:066008. https://doi.org/10.1117/1.JBO.19.6.066008
doi: 10.1117/1.JBO.19.6.066008 pubmed: 24967914
Louis DN, Suvà ML, Burger PC, Perry A, Kleihues P, Aldape KD et al (2016) Diffuse astrocytic and oligodendroglial tumours. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC, Lyon, pp 28–45
Mikami S, Oya M, Mizuno R, Kosaka T, Ishida M, Kuroda N et al (2016) Recent advances in renal cell carcinoma from a pathological point of view. Pathol Int 66:481–490. https://doi.org/10.1111/pin.12433
doi: 10.1111/pin.12433 pubmed: 27461942
Moch H, Amin MB, Argani P, Cheville J, Delahunt B, Martignoni G et al (2016) Tumours of the kidney. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds) WHO classification of tumors of the urinary system and male genital organs, 4th edn. IARC, Lyon, pp 14–17
Pinder SE, Collins LC, Fox SB, Schnitt SJ, van Deurzen CHM, Weaver DL et al (2019) Epithelial tumours of the breast. In: Lokuhetty D, White VA, Watanabe R, Cree IA (eds) WHO classification of tumours breast tumours, 5th edn. IARC, Lyon, pp 76–81
Samaratunga H, Delahunt B, Srigley JR, Berney DM, Cheng L, Evans A et al (2020) Granular necrosis: a distinctive form of cell death in malignant tumours. Pathology 52:507–514. https://doi.org/10.1016/j.pathol.2020.06.002
doi: 10.1016/j.pathol.2020.06.002 pubmed: 32561208
Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS et al (2005) Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 104:511–520. https://doi.org/10.1002/cncr.21206
doi: 10.1002/cncr.21206 pubmed: 15973740
Shaul ME, Fridlender ZG (2019) Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol 16:601–620. https://doi.org/10.1038/s41571-019-0222-4
doi: 10.1038/s41571-019-0222-4 pubmed: 31160735
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30. https://doi.org/10.3322/caac.21590
doi: 10.3322/caac.21590 pubmed: 31912902
Swierczak A, Mouchemore KA, Hamilton JA, Anderson RL (2015) Neutrophils: important contributors to tumor progression and metastasis. Cancer Metastasis Rev 34:735–751. https://doi.org/10.1007/s10555-015-9594-9
doi: 10.1007/s10555-015-9594-9 pubmed: 26361774
Venkatachalam MA (1999) Cellular pathology I: cell injury and cell death. In: Cotran RS, Kumar V, Collins T (eds) Robbins pathologic basis of disease, 6th edn. W.B. Saunders Company, Philadelphia, pp 1–29
Volpe A, Bollito E, Bozzola C, Di Domenico A, Bertolo R, Zegna L et al (2016) Classification of histologic patterns of pseudocapsular invasion in organ-confined renal cell carcinoma. Clin Genitourin Cancer 14:69–75. https://doi.org/10.1016/j.clgc.2015.07.020
doi: 10.1016/j.clgc.2015.07.020 pubmed: 26337654
Vuong L, Kotecha RR, Voss MH, Hakimi AA (2019) Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov 9:1349–1357. https://doi.org/10.1158/2159-8290.CD-19-0499
doi: 10.1158/2159-8290.CD-19-0499 pubmed: 31527133 pmcid: 6774890
Warren AY, Harrison D (2018) WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World J Urol 36:1913–1926. https://doi.org/10.1007/s00345-018-2447-8
doi: 10.1007/s00345-018-2447-8 pubmed: 30123932 pmcid: 6280811
Zhang L, Zha Z, Qu W, Zhao H, Yuan J, Feng Y et al (2018) Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis. BMC Cancer 18:870. https://doi.org/10.1186/s12885-018-4773-z
doi: 10.1186/s12885-018-4773-z pubmed: 30176824 pmcid: 6122538

Auteurs

Takashi Kuroe (T)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.

Reiko Watanabe (R)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.

Motohiro Kojima (M)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.

Ryo Morisue (R)

Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Masato Sugano (M)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.

Takeshi Kuwata (T)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.

Hitoshi Masuda (H)

Department of Urology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Shota Kusuhara (S)

Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Nobuaki Matsubara (N)

Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Shioto Oda (S)

Department of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Tetsuo Ushiku (T)

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Genichiro Ishii (G)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. gishi@east.ncc.go.jp.
Division of Innovative Pathology and Laboratory Medicine, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan. gishi@east.ncc.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH